Extended Patent Protection for Strangvac approved in the United Kingdom
Stockholm, September 20, 2024 – Intervacc AB (publ) announces that the application for supplementary protection for Strangvac, an innovative vaccine against strangles, has now been approved in the United Kingdom. This supplementary protection extends the existing patent protection from May 2031 to May 2036 on the UK market. The previously approved European patent for Strangvac is valid until May 2031. With the newly granted supplementary protection in the United Kingdom, along with previous applications in other European markets including Sweden, Benelux, Italy, Ireland, France, Spain,